Research programme: anti-interleukin-22 monoclonal antibodies - BioAtla/BioMotivAlternative Names: anti-IL-22 monoclonal antibodies - BioAtla/BioMotiv; IL-22 antibodies - BioAlta/BioMotiv; Interleukin-22 antibodies - BioAtla/BioMotiv
Latest Information Update: 22 Feb 2014
At a glance
- Originator BioAtla
- Developer BioMotiv
- Class Monoclonal antibodies
- Mechanism of Action Interleukin-22 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer; Inflammatory bowel diseases